Table of Contents Author Guidelines Submit a Manuscript
Journal of Analytical Methods in Chemistry
Volume 2014 (2014), Article ID 629343, 7 pages
http://dx.doi.org/10.1155/2014/629343
Research Article

Simple and Sensitive Analysis of Blonanserin and Blonanserin C in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry and Its Application

Research Center for Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University, Hangzhou 310003, China

Received 12 November 2013; Revised 17 December 2013; Accepted 18 December 2013; Published 11 February 2014

Academic Editor: Sibel A. Ozkan

Copyright © 2014 Yunliang Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Garcia, M. Robert, F. Peris, H. Nakamura, N. Sato, and Y. Terazawa, “The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre Study,” CNS Drugs, vol. 23, no. 7, pp. 615–625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. Lonasen(blonanserin) [product information]. Dainippon Sumitomo Pharma, Japan, 2009 (Japanese).
  3. Y. Ohno, M. Okano, J. Imaki, A. Tatara, T. Okumura, and S. Shimizu, “Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist,” Pharmacology Biochemistry and Behavior, vol. 96, no. 2, pp. 175–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. E. D. Deeks and G. M. Keating, “Blonanserin: a review of its use in the management of schizophrenia,” CNS Drugs, vol. 24, no. 1, pp. 65–84, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Yang, W.-M. Bahk, H.-S. Cho et al., “Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial,” Clinical Neuropharmacology, vol. 33, no. 4, pp. 169–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Suzuki and K. Gen, “The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT2A activity/anti-dopamine D2 activity ratio and drug-induced extrapyramidal symptoms,” Psychiatry and Clinical Neurosciences, vol. 66, no. 2, pp. 146–152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Lonansen, (Blonanserin): Prescribing Information, Dainippon Sumitomo Pharma, Osaka, Japan, 2009.
  8. Investigator’s Brochure, Dainippon Sumitomo Pharma, Osaka, Japan, 2006.
  9. M. Matsuda, M. Sakashita, T. Yamaguchi, and T. Fujii, “Determination of a novel anti-psychotic agent AD-5423 and its metabolites in plasma by high-performance liquid chromatography with fluorescence detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 15, no. 9-10, pp. 1449–1456, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Ochi, M. Sakamoto, A. Minamida et al., “Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 4, pp. 1055–1059, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Murasaki, H. Nishikawa, and T. Ishibashi, “Dopamine-serotonin antagonist: Receptor binding profile of a novel antipsychotic blonanserin,” JapaneseJournal of Clinical Psychopharmacol, vol. 11, pp. 845–854, 2008 (Japanese). View at Google Scholar
  12. T. Une and S. Kurumiya, “Pharmacological profile of blonanserin,” JapaneseJournal of Clinical Psychopharmacol, vol. 10, pp. 1263–1272, 2007 (Japanese). View at Google Scholar
  13. H. Hattori, M. Iwai, T. Ogawa et al., “Simple analysis of blonanserin, a novel antipsychotic agent, in human plasma by GC-MS,” Forensic Toxicology, vol. 28, no. 2, pp. 105–109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Saruwatari, N. Yasui-Furukori, Y. Inoue, and S. Kaneko, “Effect of dose timing in relation to food intake on systemic exposure to blonanserin,” European Journal of Clinical Pharmacology, vol. 66, no. 9, pp. 899–902, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. G. Wen, X. J. Ni, M. Zhang, X. Liu, and D. W. Shang, “Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study,” Journal of Chromatography B, vol. 15, no. 903, pp. 46–52, 2012. View at Google Scholar
  16. T. Ogawa, H. Hattori, R. Kaneko et al., “Sensitive analysis of blonanserin, a novel antipsychotic agent, in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry,” Analytical Sciences, vol. 26, no. 10, pp. 1099–1102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Zhou, M. Liu, J. Jiang, H. Y. Wang, and P. Hu, “Simultaneous determination of blonanserin and its four metabolites in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B, vol. 15, no. 939, pp. 59–66, 2013. View at Google Scholar
  18. European Medicines Agency Guideline on Validation of Bioanalytical Methods, Committee for Medicinal Products for Human Use, London, UK, 2009.